Formulary E-news :
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Unsubscribe from this list.
Formulary E-news
Modern Medicine Network
 
 
 
 
 
TOP SEARCHES: Cardiovascular disease // Fampridine-SR/ // REMS
In this issue
Comparative effectiveness
Diet drugs in final stages
New antipsychotics
Increased diabetes risk
Long-acting insulin
Ulcers in NSAID users
Key Topic Updates

Survey

This month we would like to know...

What actions has your organization taken with network pharmacies in light of recent AWP rollback?

a) Created cost-neutrality for pharmacies by re-adjusting AWP discounts
to a lower level

b) Created cost-neutrality for pharmacies by reinflating AWPs to
pre-9.26 levels, thereby retaining previous WAC-to-AWP ratios

c) Maintained existing AWP discounts, thereby garnering significant
savings from rollback for our organization

d) Transferred to a new non-AWP-based reimbursement methodology (e.g.,
WAC, AMP)

e) Not applicable

Vote in our survey, and see what other P&T committee members have to say.

Click here to vote

Contact Us
Click here to contact a Formulary editor.

Click here to contact a Formulary sales representative.

Click here to learn about direct mail, reprints and classifieds in Formulary.

October 30, 2009
Comparative effectiveness research could threaten personalized medicine, NIH director warns
The federal government’s push to control health costs through comparative effectiveness research could threaten strides in personalized medicine, in which medicines are tailored to an individual’s genetic makeup, said the National Institutes of Health (NIH) chief at a recent forum sponsored by the American Association for the Advancement of Science. More...
Three diet drugs in final stages of research and development
Three prescription diet drugs are in the final stages of development. According to USA Today, the drugs’ manufacturers still have to submit their new drug applications to the Food and Drug Administration and go through a rigorous review and approval process. More...
New antipsychotics lead to weight gain in young patients
Atypical antipsychotic agents lead to a marked and rapid weight gain in children and adolescents, according to researchers at Zucker Hillside Hospital in Glen Oaks, NY, and the Albert Einstein College of Medicine, NY. More...
Statin drugs may increase diabetes risk
Cholesterol-lowering statin drugs do not reduce the risk of diabetes and might modestly elevate the chances of developing the condition, researchers found in a pooled analysis of trial data. More...
Long-acting, once-a-day insulin dose may be best for type 2 diabetics
Adding insulin to standard diabetes drugs results in better blood sugar control for many with type-2 diabetes, and the dose and timing of insulin received can make a big difference, British researchers reported. More...
Study results show risk factors for ulcer development among NSAID users
Horizon Therapeutics Inc., a privately held biopharmaceutical company, recently presented an analysis from 2 pivotal phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine, PRNewswire reported. More...
Key Topic Updates
Medication Safety
New warnings about malignancies in pediatric patients added to labels of TNF-blockers
Initiation of antipsychotic therapy associated with hyperglycemia in older diabetic patients
Trial of sildenafil for PAH in patients with sickle cell disease terminated because of safety concerns
Drug Pipeline/Clinical Updates
Dirucotide trials for secondary progressive MS discontinued for lack of efficacy
Development of bifeprunox for maintenance treatment of schizophrenia discontinued
Regulatory/Legislative
FDA-mandated REMS now in force in pharmaceutical industry
Biogeneric drugs and brands: The future market share
Health system pharm tech roles expand
Global health concerns generate new therapies for home and abroad
CMS making changes for Medicare plans

You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.